Loading
Led ABC-02, which made gemcitabine plus cisplatin the global standard for biliary cancer, and co-led TOPAZ-1.
Juan Valle was chief investigator of ABC-02, the UK trial that established gemcitabine plus cisplatin as first-line therapy for advanced biliary tract cancer, and a lead investigator of TOPAZ-1, which added durvalumab to that backbone. He has led the ABC series of biliary trials and international guidelines on cholangiocarcinoma. He now leads research strategy at the Cholangiocarcinoma Foundation.
| Title | Journal | Year |
|---|---|---|
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02) | NEJM | 2010 |
| Biliary tract cancer | Lancet | 2021 |
The tail of long survivors is the case for chemo-immunotherapy in gallbladder cancer, where the median gain is under two months. Who lands in that tail is still unknown; no biomarker in the trial predicts it.
This is the reference European standard against which UK and NHS practice for gallbladder cancer is compared; it treats gallbladder cancer within biliary tract cancer rather than as its own disease.
For a UK patient with gallbladder cancer the nearest national guideline is about a neighbouring disease; the UK and NHS page for gallbladder cancer names the gap.
FOLFOX became the guideline second-line option for gallbladder cancer on this trial. The gain is real but small, which is why later-line care now starts with a search for a HER2 or other targetable alteration.
The prevalence estimate that made HER2 the first gallbladder-relevant target; it argues for testing every advanced gallbladder cancer, since one in five may qualify for zanidatamab or trastuzumab deruxtecan.
Shares Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial, HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?, ABC-06, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials and the tags biliary, trialist.
Shares ABC-06, The Christie NHS Foundation Trust, Biliary tract cancer (cholangiocarcinoma) and the tags biliary, trialist.
Shares ABC-02, ABC-06, Biliary tract cancer (cholangiocarcinoma) and the tags biliary, trialist.
Shares Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials and the tags biliary, trialist.
Shares Durvalumab, Biliary tract cancer (cholangiocarcinoma) and the tags biliary, trialist.
Shares the tags biliary, trialist.
Shares the tags chemotherapy, trialist.
Shares Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study, TOPAZ-1, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Durvalumab.